SEC Form 4 · accession 0001638599-16-001508
AYTU BIOPHARMA, INC · AYTU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory A Gould
Officer — Chief Financial Officer
Period of report
Nov 2, 2016
Accepted (ET)
Nov 4, 2016 · 4:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385818
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 2, 2016 | P | 66,666 | $1.50 | A | 273,565 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common StockF1 | $1.86 | Nov 2, 2016 | P | 66,666 | A | Nov 2, 2017 | Nov 2, 2021 | Common Stock | 66,666 | 66,666 | D |
| Employee Stock Option GrantF3 | $3.23 | holding | — | — | — | — | Nov 11, 2015 | Common Stock | 20,834 | 20,834 | D |
| Employee Stock Option GrantF4 | $3.23 | holding | — | — | — | — | Jul 7, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The shares of stock and warrants were purchased at a purchase price per unit of $1.50.
- F2Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.
- F3These options are 100% vested.
- F433.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates.